AI Market Cap Pro
← Back to Scanner Pricing
📅 Next earnings: November 02, 2026

Vertex Pharmaceuticals Incorpor (VRTX) — Pre-Earnings Stock Analysis

Healthcare, Biotechnology

$503.90
Current Price
$127.6B
Market Cap
29.3
Trailing P/E
$571
Analyst Target
28
Analysts
Buy
Rating

🔥 Get VRTX Targets Before Earnings

Pre-earnings entry zone, analyst PE target, 3-day and 5-day implied move, and stop loss — all unlocked with a $5/month subscription.

Unlock Full Analysis →

About Vertex Pharmaceuticals Incorpor (VRTX)

Vertex Pharmaceuticals Incorpor trades on NASDAQ under the ticker VRTX. The company operates in the Healthcare sector — specifically Biotechnology.

Current analyst consensus rating: Buy with a $571 price target based on 28 analyst opinions.

EPS (trailing): $17.17  |  Market Cap: $127.6B

Healthcare Biotechnology

Pre-Earnings Trading Strategy for VRTX

Trading stocks before earnings requires understanding three key variables: the implied move (what the options market expects), the historical beat rate for the sector, and the current momentum leading into the report.

For VRTX, the next earnings report is scheduled for November 02, 2026.

The implied move is calculated using at-the-money straddles — if the straddle is priced at X%, the market is pricing in approximately a ±X% move in either direction around the earnings release.

How AI Market Cap Finds Pre-Earnings Setups

Our pre-earnings momentum scanner scores VRTX across five factors to identify high-conviction setups:

The Pro subscription shows the full target range, stop loss, and implied move for VRTX and all 20+ stocks in the current earnings window.